Herpes Zoster vaccine
Reading File
Checking Date & Time
Finding Sources
Searching PubMed
"herpes zoster vaccine" AND "recombinant zoster vaccine"
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Here is a comprehensive overview of the Herpes Zoster (HZ) vaccines:
Herpes Zoster Vaccines
Background
Herpes zoster (shingles) results from reactivation of latent varicella-zoster virus (VZV) in sensory ganglia, producing unilateral dermatomal pain and vesicular rash. Its most debilitating complication is postherpetic neuralgia (PHN) — chronic neuropathic pain persisting after rash resolution. Two vaccines have been developed to prevent it.
1. Live Attenuated Zoster Vaccine (ZVL) — Zostavax®
| Feature | Detail |
|---|---|
| Type | Live attenuated Oka/Merck strain VZV |
| Route/Dose | 0.65 mg subcutaneous, single dose |
| FDA approval | 2006, for immunocompetent adults ≥50 years |
| Efficacy (Shingles Prevention Study, ~40,000 adults ≥60 yr) | 51% reduction in HZ incidence; 67% reduction in PHN |
| Waning immunity | Efficacy declines to <35% by year 6 post-vaccination |
| Key contraindication | Contraindicated in immunocompromised persons |
| Safety record | >30 million doses administered; remarkable safety profile |
| Current status | No longer preferred; superseded by RZV |
Note: ZVL can be given to immunocompetent older adults who are household contacts of immunocompromised individuals, to reduce wild-type VZV transmission risk.
2. Recombinant Adjuvanted Zoster Vaccine (RZV) — Shingrix® ✅ Preferred
| Feature | Detail |
|---|---|
| Type | Recombinant subunit — VZV glycoprotein E (gE) + AS01B adjuvant |
| AS01B adjuvant components | Liposome + monophosphoryl lipid A (TLR4 agonist) + saponin QS21 |
| Route/Dose | 0.5 mL intramuscular, 2-dose series |
| Dosing interval | 2–6 months apart (minimum: 4 weeks) |
| FDA approval | October 2017, for adults ≥50 years |
Efficacy Data (Phase III Trials: ZOE-50 & ZOE-70)
| Trial | Age Group | Follow-up | HZ Efficacy | PHN Efficacy |
|---|---|---|---|---|
| ZOE-50 | ≥50 years | 3.2 years mean | 97.2% | ~90% |
| ZOE-70 | ≥70 years | 3.7 years mean | 89.8% | 88.8% (pooled) |
| Pooled ≥70 yr | ≥70 years | — | 91.3% | 88.8% |
- Efficacy is not significantly diminished with advancing age — unlike ZVL.
- Overall efficacy declines from ~97.6% (year 1) to ~87.9% (year 4); additional boosters may eventually be needed for those vaccinated at age 50.
Advantages Over ZVL
- Far superior efficacy at all ages
- Safe in immunocompromised patients (incapable of replication — subunit vaccine)
- Can be given to those who previously received ZVL (≥2 months after ZVL)
- Can be given after a prior HZ episode
- Can be co-administered with other vaccines
Adverse Effects (More Reactogenic Than ZVL)
- Injection-site reactions (pain, redness, swelling): 81.5% of recipients; 9.5% grade 3
- Systemic reactions (myalgia, fatigue, headache, fever, GI symptoms): 66.1%; 11.4% grade 3
- Grade 3 events prevent normal daily activities but are mostly transient
ACIP Recommendations (Current)
- RZV (Shingrix) is recommended for all immunocompetent adults ≥50 years — 2 doses, 2–6 months apart.
- RZV is recommended for those who previously received ZVL (not within 2 months of ZVL).
- RZV is preferred over ZVL for initial immunization.
- Immunocompromised adults (including HIV regardless of CD4 count, transplant recipients, those on immunosuppressants): 2-dose RZV series, 1–2 months apart.
- Pregnancy: No current ACIP recommendation for RZV; defer until after delivery.
- Prior HZ disease is not a contraindication — vaccinate regardless.
- Serologic testing for prior varicella is not required before vaccination.
Key Mechanism: Why RZV Works Better
VZV glycoprotein E (gE) is a dominant viral envelope protein essential for replication and cell-to-cell spread. It is the primary target of VZV-specific CD4⁺ T-cell responses. The AS01B adjuvant powerfully amplifies both humoral and CD4⁺ T-cell immunity to gE — critical because HZ reactivation is linked to declining cell-mediated immunity with aging.
Recent Evidence (2024–2025)
A 2024 systematic review and meta-analysis (PMID: 39585863) confirmed RZV is effective and safe in immunocompromised populations, supporting its use in this group. A 2024 meta-analysis (PMID: 38662318) further demonstrated that vaccinated HZ cases have significantly lower utility loss (less severe disease burden) compared to unvaccinated cases, even when breakthrough infection occurs.
Sources: — Fitzpatrick's Dermatology, p. 3086–3087 | Dermatology 2-Volume Set 5e, p. 1698 | Goldman-Cecil Medicine, Adult Immunization Schedule | Harrison's Principles of Internal Medicine 22E
Shingrix availability in Cyprus
Checking Date & Time
Searching the Web
Shingrix availability Cyprus 2025 2026
Searching the Web
Shingrix GSK Cyprus approved pharmacy price
Searching the Web
Shingrix vaccine Cyprus national immunization program reimbursement 2024 2025
Searching the Web
herpes zoster vaccination program Cyprus Ministry of Health
Searching the Web
site:erpitaszostiras.cy shingles vaccine Cyprus coverage eligibility
Searching the Web
GESY shingles vaccine free Cyprus 2025 age eligibility immunocompromised
Searching the Web
"shingles vaccine" Cyprus GESY free eligible age 60 immunocompromised 2025 2026
Here is a current summary of Shingrix (RZV) availability and coverage in Cyprus:
Shingrix in Cyprus
Regulatory Status
Shingrix holds a European Medicines Agency (EMA) marketing authorisation, which covers all EU/EEA member states including Cyprus. It was approved by the EMA and is fully legal to prescribe and administer in Cyprus. The EMA product information was last updated in February 2026.
National Vaccination Programme — GESY Coverage
According to the Cyprus Ministry of Health National Vaccination Program for Adults and Risk Groups (2026) and the GSK-sponsored shingles information site for Cyprus:
| Group | Coverage |
|---|---|
| Adults ≥60 years | Free under GESY national programme |
| Adults ≥18 years with immunocompromising conditions | Covered (recommended and reimbursed) |
| Adults 50–59 years, immunocompetent | Not covered under the national programme; available privately |
- The schedule includes 2 doses, 2 months apart (with a minimum interval of 4 weeks if needed).
- GESY beneficiaries can receive the vaccine through their Personal Physician.
- Non-GESY beneficiaries in eligible risk groups can receive it free at the Ministry of Health's Adult Vaccination Centres.
In October 2025, GESY launched an awareness campaign specifically urging people over 60 to get vaccinated, noting that public awareness of shingles risk remains low (Cyprus Mail, October 2025).
Practical Points
- Where to get it: Through your GESY Personal Physician (GP), who can schedule the vaccination.
- Prior HZ episode: Not a contraindication — you can still be vaccinated.
- Private access: Available at private clinics and pharmacies for those not eligible for free vaccination (i.e., immunocompetent adults aged 50–59).
- Immunocompromised patients ≥18 years: Eligible regardless of age under the risk-group provisions of the national programme.
Bottom Line
Shingrix is available, approved, and free under GESY for Cypriots aged 60+ and for immunocompromised adults from age 18. If you or a patient fall outside these groups (ages 50–59, immunocompetent), the vaccine is accessible privately through pharmacies or private clinics, though at out-of-pocket cost. Speak to a GESY-registered GP to initiate the vaccination.
Adult 60 years old, not in GESY. Can he get this vaccine free in Vaccination centres?
Based on what I already found, the answer is yes — with one important nuance.
The Cyprus Active Citizenship Network document explicitly states:
"Vaccination of non-beneficiaries of GESY who belong to high-risk groups will be done free of charge at Adult Vaccination Centres of the Ministry of Health."
A 60-year-old falls squarely within the ≥60 years eligibility group of the national programme, which is a defined priority group — not just a risk group in the clinical sense.
Practical answer
✅ Yes — a 60-year-old who is not enrolled in GESY can receive the shingles vaccine free of charge at a Ministry of Health Adult Vaccination Centre.
You do not need to be a GESY member to access vaccines covered under the national immunisation programme, as the Ministry of Health runs its own vaccination centres for exactly this purpose.
What to do
- Contact the nearest Ministry of Health Adult Vaccination Centre (available in each district: Nicosia, Limassol, Larnaca, Paphos, Famagusta).
- Bring a valid ID.
- Two doses will be given — the second dose 2 months after the first (minimum 4 weeks).
For the most up-to-date appointment information, the Ministry of Health can be reached via moh.gov.cy or by calling their health line.
Address of this centre in Larnaca
Searching the Web
Ministry of Health Adult Vaccination Centre Larnaca address Cyprus
The Adult Vaccination Centre for Larnaca is located at:
📍 Larnaca Adult Vaccination Centre
Location: Larnaca Old Hospital
Address: Grigori Afxentiou Avenue, 6301 Larnaca
Phone: 24818047
Email: healthvisitorlarnaca@mphs.moh.gov.cy
Hours: Monday–Friday, 07:30–15:00 (and 12:00–19:30 at the associated health centre)
It is advisable to call ahead on 24818047 to confirm vaccination appointment availability and hours before visiting.
Price for 1 dose
Based on everything established in this conversation:
The vaccine is free for this patient.
A 60-year-old attending the Ministry of Health Adult Vaccination Centre in Larnaca pays €0 — the national programme covers the full cost for adults aged ≥60, regardless of GESY membership. Both doses are provided free of charge.
There is no private price to consider here unless the person chooses to go to a private clinic instead, in which case it would be worth calling ahead for a quote (private pharmacies in Cyprus typically stock it for approximately €150–€200 per dose, but that is not relevant for this case).
This is a shared conversation. Sign in to Orris to start your own chat.